© 1995 American Heart Association, Inc.
Articles |
Phenotypic Correction of Hypercholesterolemia in ApoE-Deficient Mice by Adenovirus-Mediated In Vivo Gene Transfer
From the Department of Molecular and Cell Biology, Genetic Therapy Inc, Gaithersburg, Md.
Correspondence to Alan McClelland, Department of Molecular and Cell Biology, Genetic Therapy, Inc, 938 Clopper Rd, Gaithersburg, MD 20878.
Abstract To investigate the potential use of apoE in gene therapy of hyperlipidemias, an adenoviral vector was constructed that contained the human apoE3 cDNA under the control of the RSV promoter (Av1RE). Transduction of HepG2 cells resulted in the overexpression of human apoE secreted into the culture medium. Intravenous injection of 5x1011 Av1RE vector particles into apoE-deficient mice resulted in expression of human apoE3 in mouse plasma at levels of 1.2±0.4 µg/mL (mean±SEM, n=5) 7 days after injection. Mice injected with the control vector Av1Lacz4 did not express detectable levels of human apoE. Average plasma cholesterol concentrations were reduced approximately eightfold from 737.5±118 mg/dL (mean±SEM, n=6) to 98.2±4.4 mg/dL (mean±SEM, n=5) and were unaffected in the control vector group. Expression of human apoE resulted in a shift in the plasma lipoprotein distribution from primarily VLDL and LDL in the control mice to predominantly HDL in the Av1RE-treated group. Western blot analysis of fast protein liquid chromatography–fractionated mouse plasma showed that the human apoE protein was associated with VLDL, LDL, and HDL. Correction of the hyperlipidemic condition found in the apoE-knockout mouse strain by direct in vivo gene transfer establishes the potential of this approach for treatment of hyperlipidemia caused by apoE deficiency or malfunction in human disease.
Key Words: atherosclerosis • apolipoprotein E • gene therapy • lipoproteins
This article has been cited by other articles:
 |
|
 |
|
  J. Heeren, U. Beisiegel, and T. Grewal Apolipoprotein E Recycling: Implications for Dyslipidemia and Atherosclerosis Arterioscler Thromb Vasc Biol, March 1, 2006; 26(3): 442 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Harris, I. R. Graham, S. Schepelmann, A. K. Stannard, M. L. Roberts, B. L. Hodges, V. Hill, A. Amalfitano, D. G. Hassall, J. S. Owen, et al. Acute regression of advanced and retardation of early aortic atheroma in immunocompetent apolipoprotein-E (apoE) deficient mice by administration of a second generation [E1-, E3-, polymerase-] adenovirus vector expressing human apoE Hum. Mol. Genet., January 1, 2002; 11(1): 43 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-a. Kawashiri, Y. Zhang, D. Usher, M. Reilly, E. Puré, and D. J. Rader Effects of coexpression of the LDL receptor and apoE on cholesterol metabolism and atherosclerosis in LDL receptor-deficient mice J. Lipid Res., June 1, 2001; 42(6): 943 - 950. [Abstract] [Full Text]
|
|
|
|
|
|
K. C-W. Yu, Y. Jiang, W. Chen, and A. D. Cooper Rapid initial removal of chylomicron remnants by the mouse liver does not require hepatically localized apolipoprotein E J. Lipid Res., November 1, 2000; 41(11): 1715 - 1727. [Abstract] [Full Text]
|
|
|
|
|
|
T. Athanasopoulos, J. S. Owen, D. Hassall, M. G. Dunckley, J. Drew, J. Goodman, A. D. Tagalakis, D. R. Riddell, and G. Dickson Intramuscular injection of a plasmid vector expressing human apolipoprotein E limits progression of xanthoma and aortic atheroma in apoE-deficient mice Hum. Mol. Genet., October 1, 2000; 9(17): 2545 - 2551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Desurmont, J.-M. Caillaud, F. Emmanuel, P. Benoit, J. C. Fruchart, G. Castro, D. Branellec, J.-M. Heard, and N. Duverger Complete Atherosclerosis Regression After Human ApoE Gene Transfer in ApoE-Deficient/Nude Mice Arterioscler Thromb Vasc Biol, February 1, 2000; 20(2): 435 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tsukamoto, R. Tangirala, S. H. Chun, E. Pure, and D. J. Rader Rapid Regression of Atherosclerosis Induced by Liver-Directed Gene Transfer of ApoE in ApoE-Deficient Mice Arterioscler Thromb Vasc Biol, September 1, 1999; 19(9): 2162 - 2170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Hasty, M. F. Linton, L. L. Swift, and S. Fazio Determination of the lower threshold of apolipoprotein E resulting in remnant lipoprotein clearance J. Lipid Res., August 1, 1999; 40(8): 1529 - 1538. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. D. Lake-Bruse, F. M. Faraci, E. G. Shesely, N. Maeda, C. D. Sigmund, and D. D. Heistad Gene transfer of endothelial nitric oxide synthase (eNOS) in eNOS-deficient mice Am J Physiol Heart Circ Physiol, August 1, 1999; 277(2): H770 - H776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Reardon, L. Blachowicz, K. M. Watson, E. Barr, and G. S. Getz Association of human apolipoprotein E with lipoproteins secreted by transfected McA RH7777 cells J. Lipid Res., July 1, 1998; 39(7): 1372 - 1381. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. D Gerard and D. Collen Adenovirus gene therapy for hypercholesterolemia, thrombosis and restenosis Cardiovasc Res, September 1, 1997; 35(3): 451 - 458. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Leiden Adenovirus-Mediated Gene Transfer as an In Vivo Probe of Lipoprotein Metabolism Circulation, November 1, 1996; 94(9): 2046 - 2051. [Full Text]
|
|
|
|
 |
|
 A. D. Tagalakis, I. R. Graham, D. R. Riddell, J. G. Dickson, and J. S. Owen Gene Correction of the Apolipoprotein (Apo) E2 Phenotype to Wild-type ApoE3 by in Situ Chimeraplasty J. Biol. Chem., April 13, 2001; 276(16): 13226 - 13230. [Abstract] [Full Text] [PDF]
|
|